Literature DB >> 23848158

Decrease in pool of T lymphocytes with surface phenotypes of effector and central memory cells under influence of TCR transgenic β-chain expression.

Yu Yu Silaeva1, A A Kalinina, M S Vagida, L M Khromykh, A V Deikin, T G Ermolkevich, E R Sadchikova, I L Goldman, D B Kazansky.   

Abstract

Peripheral T lymphocytes can be subdivided into naïve and antigen-experienced T cells. The latter, in turn, are represented by effector and central memory cells that are identified by different profiles of activation markers expression, such as CD44 and CD62L in mice. These markers determine different traffic of T lymphocytes in the organism, but hardly reproduce real antigenic experience of a T lymphocyte. Mechanisms of homeostasis maintenance of T lymphocytes with different activation phenotypes remain largely unknown. To investigate impact of T cell receptor (TCR) transgenic chains on formation of T lymphocytes, their peripheral survival and activation surface phenotypes, we have generated the transgenic mouse strain expressing transgenic β-chain of TCR 1D1 (belonging to the Vβ6 family) on the genetic background B10.D2(R101). Intrathymic development of T cells in these transgenic mice is not impaired. The repertoire of peripheral T lymphocytes in these mice contains 70-80% of T cells expressing transgenic β-chain and 20-30% of T cells expressing endogenous β-chains. The ratio of peripheral CD4⁺CD8⁻ and CD4⁻CD8⁺ T lymphocytes remained unchanged in the transgenic animals, but the percent of T lymphocytes with the "naïve" phenotype CD44CD62L⁺ was significantly increased, whereas the levels of effector memory CD44CD62L⁻ and central memory CD44CD62L⁺ T lymphocytes were markedly decreased in both subpopulations. On the contrary, T lymphocytes expressing endogenous β-chains had surface phenotype of activated T cells CD44⁺. Thus, for the first time we have shown that the pool of T lymphocytes with different activation phenotypes depends on the structure of T cell receptors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23848158     DOI: 10.1134/S0006297913050143

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  6 in total

1.  Genome Editing As an Approach to the Study of in Vivo Transcription Reprogramming.

Authors:  Y Y Silaeva; V A Kalmykov; E A Varlamova; E N Korshunov; D S Korshunova; M V Kubekina; A A Shtil; I B Roninson; A V Deykin
Journal:  Dokl Biochem Biophys       Date:  2020-04-27       Impact factor: 0.788

2.  PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.

Authors:  Yuan Zhuang; Sihan Li; Huihui Wang; Jingbo Pi; Yuhui Xing; Guang Li
Journal:  J Cancer Res Clin Oncol       Date:  2018-08-03       Impact factor: 4.553

3.  Dominant role of the α-chain in rejection of tumor cells bearing a specific alloantigen in TCRα transgenic mice and in in vitro experiments.

Authors:  Maria Zamkova; Anastasiya Kalinina; Yuliya Silaeva; Nadezhda Persiyantseva; Alexandra Bruter; Alexey Deikin; Ludmila Khromykh; Dmitry Kazansky
Journal:  Oncotarget       Date:  2019-08-06

4.  Novel transgenic mice with Cre-dependent co-expression of GFP and human ACE2: a safe tool for study of COVID-19 pathogenesis.

Authors:  Alexandra V Bruter; Diana S Korshunova; Marina V Kubekina; Petr V Sergiev; Anastasiia A Kalinina; Leonid A Ilchuk; Yuliya Yu Silaeva; Eugenii N Korshunov; Vladislav O Soldatov; Alexey V Deykin
Journal:  Transgenic Res       Date:  2021-04-14       Impact factor: 2.788

5.  Formation of a Unique Population of CD8+ T Lymphocytes after Adoptive Transfer of Syngeneic Splenocytes to Mice with Lymphopenia.

Authors:  Yu Yu Silaeva; A A Kalinina; L M Khromykh; A V Deykin; D B Kazansky
Journal:  Dokl Biochem Biophys       Date:  2021-03-05       Impact factor: 0.788

6.  Altered Hepa1-6 cells by dimethyl sulfoxide (DMSO)-treatment induce anti-tumor immunity in vivo.

Authors:  Zhengyu Jiang; Hongxia Zhang; Ye Wang; Bin Yu; Chen Wang; Changcheng Liu; Juan Lu; Fei Chen; Minjun Wang; Xinlu Yu; Jiahao Lin; Xinghua Pan; Pin Wang; Haiying Zhu
Journal:  Oncotarget       Date:  2016-02-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.